SCHEMBL8963994

SCHEMBL8963994

O=C(c1cncc(Br)c1)c1cccc(N2CCCN(C(=O)Cc3ccccc3)CC2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.48
KDM4E B2RXH2 4/20 0.47
ME2 P23368 2/20 0.45
ME1 P48163 2/20 0.45
ME3 Q16798 2/20 0.45
ALDH1A1 P00352 5/20 0.43
MAPT P10636 2/20 0.43
HTT P42858 3/20 0.41
GAA P10253 2/20 0.41
ALOX12 P18054 1/20 0.41
ALOX15 P16050 1/20 0.41
HSD17B14 Q9BPX1 1/20 0.41
HPGD P15428 2/20 0.41
LMNA P02545 1/20 0.41
HSD17B10 Q99714 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
SMYD2 Q9NRG4 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8964048 0.92 HSD17B14 (0.41) GBA1KDM4EME2ME1ME3
SCHEMBL8964078 0.92 SMN1; SMN2 (0.49) GBA1KDM4EALDH1A1MAPTHTT
SCHEMBL8963478 0.86 KDM4E (0.49) GBA1KDM4EME2ME1ME3
SCHEMBL8964155 0.85 HSD17B14 (0.43) KDM4EALDH1A1MAPTHTTGAA
SCHEMBL8964294 0.85 CASP1 (0.48) KDM4EALDH1A1MAPTHTTALOX15
SCHEMBL8964479 0.84 CASP1 (0.47) ALDH1A1MAPTHTTALOX15HSD17B14
SCHEMBL8970084 0.83 PRKCQ (0.49) GBA1KDM4EME2ME1ME3
SCHEMBL8964005 0.82 HSD17B14 (0.43) KDM4EALDH1A1MAPTHTTGAA
SCHEMBL8964092 0.82 CKS1B (0.46) KDM4EALDH1A1MAPTHTTGAA
SCHEMBL8964020 0.82 HSD17B14 (0.43) KDM4EALDH1A1MAPTHTTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140221334-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-08-07 US disclosed
US-8741931-B2 Kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2014-06-03 US disclosed
US-20120214799-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-08-23 US disclosed
US-8188071-B2 Amino substituted pyridines as potent kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221334-A1 KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K6 GBA1 1257/4885KDM4E 990/4885ME2 1934/4885
US-20120214799-A1 KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K6 GBA1 1257/4885KDM4E 990/4885ME2 1934/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.